Simvastatin (Zocor) Therapy in Sickle Cell Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Sickle Cell Disease
Interventions
DRUG

Simvastatin

Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.

Trial Locations (1)

94609

Children's Hospital and Research Center Oakland, Oakland

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

FDA Office of Orphan Products Development

FED

lead

UCSF Benioff Children's Hospital Oakland

OTHER

NCT00508027 - Simvastatin (Zocor) Therapy in Sickle Cell Disease | Biotech Hunter | Biotech Hunter